On-shore High Potency Pharma Manufacturing in the US and EU

For many years, there has been a shift towards outsourcing chemical pharmaceutical manufacturing to countries such as China and India, where labor is cheaper. While this has resulted in cost savings for pharmaceutical companies, it has also led to concerns about quality control, intellectual property theft, and supply chain disruptions.

On the other hand, on-shoring chemical pharmaceutical manufacturing to the US and EU offers several advantages, particularly in the production of small-volume, high-potency active pharmaceutical ingredients (HPAPI). Here are some of the key benefits:

Quality Control

On-shoring chemical pharmaceutical manufacturing allows for better quality control, as companies can oversee the entire manufacturing process from start to finish. This ensures that the final product meets the highest quality standards and is safe for consumption. In addition, on-shoring enables companies to address any quality issues quickly and efficiently, minimizing the risk of product recalls and reputational damage.

Intellectual Property Protection

One of the major concerns with outsourcing pharmaceutical manufacturing to countries such as China and India is the risk of intellectual property theft. On-shoring manufacturing to the US and EU provides greater protection for intellectual property, as these countries have stronger intellectual property laws and regulations. This helps to safeguard valuable research and development efforts, and protects companies from potential legal disputes.

Supply Chain Resilience

The COVID-19 pandemic has highlighted the importance of supply chain resilience, particularly in the pharmaceutical industry. On-shoring chemical pharmaceutical manufacturing to the US and EU helps to ensure a reliable and resilient supply chain, as companies can reduce their dependence on overseas suppliers and minimize the risk of supply chain disruptions.

Local Job Creation

On-shoring chemical pharmaceutical manufacturing to the US and EU also provides a boost to the local economy through job creation. This is particularly important in regions that have suffered from high unemployment rates, as it helps to create new jobs and support economic growth.

On-shoring chemical pharmaceutical manufacturing to the US and EU offers several advantages, particularly in the production of small-volume, high-potency active pharmaceutical ingredients (API). These benefits include better quality control, intellectual property protection, supply chain resilience, and local job creation. As such, it is important for pharmaceutical companies to consider the advantages of on-shoring when evaluating their manufacturing strategies.